Merck Sharp + Dohme Corp.

Ambrx, Inc.

Ambryx, Inc.

Grigori Ermakov

Leonard G Presta

Xiao Min Schebye

Douglas J Hodges

Nick Knudsen

Elisabetta Bianchi

Robert M Garbaccio

Federica Orvieto

Wolfgang Seghezzi

Dennis P Gately

Paul E Carrington

Anthony Manibusan

Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors

Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.

Anti-GITR antibodies

Growing community of inventors

Santa Clara, CA, United States of America

Grigori Ermakov